197 related articles for article (PubMed ID: 21879448)
21. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer.
Botrugno OA; Santoro F; Minucci S
Cancer Lett; 2009 Aug; 280(2):134-44. PubMed ID: 19345000
[TBL] [Abstract][Full Text] [Related]
22. Isoform-selective HDAC inhibitors: closing in on translational medicine for the heart.
McKinsey TA
J Mol Cell Cardiol; 2011 Oct; 51(4):491-6. PubMed ID: 21108947
[TBL] [Abstract][Full Text] [Related]
23. Histone deacetylases as regulators of inflammation and immunity.
Shakespear MR; Halili MA; Irvine KM; Fairlie DP; Sweet MJ
Trends Immunol; 2011 Jul; 32(7):335-43. PubMed ID: 21570914
[TBL] [Abstract][Full Text] [Related]
24. Strategies in developing promising histone deacetylase inhibitors.
Zhang L; Fang H; Xu W
Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
[TBL] [Abstract][Full Text] [Related]
25. An acidic polysaccharide of Panax ginseng ameliorates experimental autoimmune encephalomyelitis and induces regulatory T cells.
Hwang I; Ahn G; Park E; Ha D; Song JY; Jee Y
Immunol Lett; 2011 Aug; 138(2):169-78. PubMed ID: 21524666
[TBL] [Abstract][Full Text] [Related]
26. Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells.
Wang L; de Zoeten EF; Greene MI; Hancock WW
Nat Rev Drug Discov; 2009 Dec; 8(12):969-81. PubMed ID: 19855427
[TBL] [Abstract][Full Text] [Related]
27. HDAC inhibitors in models of inflammation-related tumorigenesis.
Glauben R; Sonnenberg E; Zeitz M; Siegmund B
Cancer Lett; 2009 Aug; 280(2):154-9. PubMed ID: 19101082
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylases as targets in autoimmune and autoinflammatory diseases.
Hamminger P; Rica R; Ellmeier W
Adv Immunol; 2020; 147():1-59. PubMed ID: 32981634
[TBL] [Abstract][Full Text] [Related]
29. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
30. Combination of isoform-selective histone/protein deacetylase inhibitors improves Foxp3+ T-regulatory cell function.
Beier UH; Wang L; Hancock WW
Cell Cycle; 2012 Sep; 11(18):3351-2. PubMed ID: 22918251
[TBL] [Abstract][Full Text] [Related]
31. Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint.
Magnaghi-Jaulin L; Eot-Houllier G; Fulcrand G; Jaulin C
Cancer Res; 2007 Jul; 67(13):6360-7. PubMed ID: 17616695
[TBL] [Abstract][Full Text] [Related]
32. Histone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.
Beier UH; Akimova T; Liu Y; Wang L; Hancock WW
Curr Opin Immunol; 2011 Oct; 23(5):670-8. PubMed ID: 21798734
[TBL] [Abstract][Full Text] [Related]
33. Targeting histone deacetylases for the treatment of cancer and inflammatory diseases.
Huang L
J Cell Physiol; 2006 Dec; 209(3):611-6. PubMed ID: 17001696
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylases and their role in asthma.
Royce SG; Karagiannis TC
J Asthma; 2012 Mar; 49(2):121-8. PubMed ID: 22233225
[TBL] [Abstract][Full Text] [Related]
35. Regulating regulatory T cells to achieve transplant tolerance.
Tao R; Hancock WW
Hepatobiliary Pancreat Dis Int; 2007 Aug; 6(4):348-57. PubMed ID: 17690028
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
37. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
38. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
39. Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti R; Conte M; Altucci L
Antioxid Redox Signal; 2015 Jul; 23(1):99-126. PubMed ID: 24382114
[TBL] [Abstract][Full Text] [Related]
40. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
